Ebook: Atypical Antipsychotics

The introduction of chlorpromazine in 1953, and haloperidol in 1958, into clinical practice dramatically altered the therapy of schizophrenic patients. Although representing by no means a cure for this severe psychiatric ill­ ness, it allowed, for the first time, to adequately control the severe hallu­ cinations and delusional beliefs which prevent these patients from leading a more or less independent life. Indeed these antipsychotics (and the many congeners that were to follow) significantly reduced the number ofchronic schizophrenic inpatients in psychiatric clinics all over the world. However soon after their introduction it became clear that, like all other available drugs, antipsychotics were by no means miracle drugs. In fact, two major problems appeared. First, the antipsychotics had very little effect on the so-called negative or defect symptoms, like social isolation, apathy and anhedonia, and secondly virtually all antipsychotics produced a number of side-effects, of which the neurological (often called extra­ pyramidal) side-effects were the most troublesome. Especially the tardive dyskinesia, which occurred in about 15 to 20% of the patients after pro­ longed treatment, represented a major problem in the treatment of schizo­ phrenic patients.

---

The present volume deals with drugs which play an important role in the therapy of schizophrenia. It describes the introduction of the first antipsychotics on the market and the importance of clozapine, a prototype for atypical antipsychotics, for further investigation of other potentially atypical antipsychotics, which may have an important impact on the therapy and especially the well being of schizophrenic patients, and their introduction in clinical practice. The book is written by experts in the field of schizophrenia both from a clinical and preclinical point of view. It is of interest to practising psychiatrists, to neuroscientists working in the pharmaceutical industry and also to medical students.

---

The present volume deals with drugs which play an important role in the therapy of schizophrenia. It describes the introduction of the first antipsychotics on the market and the importance of clozapine, a prototype for atypical antipsychotics, for further investigation of other potentially atypical antipsychotics, which may have an important impact on the therapy and especially the well being of schizophrenic patients, and their introduction in clinical practice. The book is written by experts in the field of schizophrenia both from a clinical and preclinical point of view. It is of interest to practising psychiatrists, to neuroscientists working in the pharmaceutical industry and also to medical students.
Content:
Front Matter....Pages I-XI
Front Matter....Pages 1-1
Introduction to schizophrenia....Pages 3-17
From first to second generation antipsychotics....Pages 19-33
Animal models for schizophrenia: an introduction....Pages 35-53
Front Matter....Pages 55-55
Receptor profile of antipsychotics....Pages 57-81
Regional selectivity of antipsychotic drugs....Pages 83-98
Screening models for antipsychotic drugs....Pages 99-119
Simulation models for schizophrenia....Pages 121-142
Front Matter....Pages 143-143
Clozapine: the first atypical antipsychotic....Pages 145-162
Dopamine receptor subtypes and schizophrenia: a clinical perspective....Pages 163-190
Multireceptor atypical antipsychotic drugs....Pages 191-213
New discoveries in the development of antipsychotics with novel mechanisms of action: beyond the atypical antipsychotics with serotonin dopamine antagonism....Pages 215-232
Back Matter....Pages 233-236

---

The present volume deals with drugs which play an important role in the therapy of schizophrenia. It describes the introduction of the first antipsychotics on the market and the importance of clozapine, a prototype for atypical antipsychotics, for further investigation of other potentially atypical antipsychotics, which may have an important impact on the therapy and especially the well being of schizophrenic patients, and their introduction in clinical practice. The book is written by experts in the field of schizophrenia both from a clinical and preclinical point of view. It is of interest to practising psychiatrists, to neuroscientists working in the pharmaceutical industry and also to medical students.
Content:
Front Matter....Pages I-XI
Front Matter....Pages 1-1
Introduction to schizophrenia....Pages 3-17
From first to second generation antipsychotics....Pages 19-33
Animal models for schizophrenia: an introduction....Pages 35-53
Front Matter....Pages 55-55
Receptor profile of antipsychotics....Pages 57-81
Regional selectivity of antipsychotic drugs....Pages 83-98
Screening models for antipsychotic drugs....Pages 99-119
Simulation models for schizophrenia....Pages 121-142
Front Matter....Pages 143-143
Clozapine: the first atypical antipsychotic....Pages 145-162
Dopamine receptor subtypes and schizophrenia: a clinical perspective....Pages 163-190
Multireceptor atypical antipsychotic drugs....Pages 191-213
New discoveries in the development of antipsychotics with novel mechanisms of action: beyond the atypical antipsychotics with serotonin dopamine antagonism....Pages 215-232
Back Matter....Pages 233-236
....